Strong financials, accelerated growth trends, and a guidance update reflect on a favorable outlook for Medtronic plc (NYSE:MDT). The company is exploring prospects within advanced systems and technologies, while strategic collaborations are delivering additional growth opportunities. Recent strategic moves support management’s ambitions of turning the company into a multi-platform powerhouse. Medtronic’s growth story looks promising, but there’s a bigger question: Can its established businesses keep pace with its ambitious new bets, or is the company stretching itself too thin?
Drivers of the Next Growth Phase
Medtronic’s Cardiac Ablation Solutions (CAS) is a key growth enabler and has been garnering attention as of late, following impressive growth figures in recent quarters. CFO Thierry Piéton acknowledged the segment during the company’s fiscal 2026 annual release, highlighting that it is annualizing at more than $2 billion in revenue. CAS surpassed $2 billion in trailing 12-month revenue in Q1 FY27, ahead of management’s target.
It delivered a solid first quarter print, as double-digit year-over-year growth was witnessed across all major segments. Medical Surgical went up by 10%, while Neuroscience and Diabetes posted 10.3% and 16.9% growth figures, respectively. Cardiovascular remained a standout performer delivering a 19.5% jump. This resulted in 13.7% organic and reported topline growth, which clocked in at $9.756 billion. However, an extra fiscal week contributed approximately $570 million to quarterly revenue, boosting the reported growth rate. The Q1 adjusted earnings came in at $1.45 per share.
Its recent $700 million strategic investment in Cornerstone Robotics includes rights to distribute the Sentire Surgical System in select markets outside the US, where it has regulatory approval. For Medtronic, this results in high-margin prospects across the robotic-assisted surgery space, where adoption trends are still low. It also diversifies the company’s revenue mix covering broader procedure volumes, as Sentire will complement its existing Hugo robotic-assisted surgery system. Medtronic’s $700 million robotics bet could open another growth avenue. But is this the breakthrough that could reshape its growth trajectory, or an expensive gamble?
What Could Go Wrong
It is also worth mentioning that scaling up rapidly within robotics hardware can be a highly capital-intensive bet. At least in the near-term, the impact will be unfavorable on underlying margins. The coming few quarters shall offer more visibility into how much are these high-margin procedures delivering at scale.
The company also faces stiff competition within the core segments that it plans to scale across. Boston Scientific and Stryker are well-reputed names within surgical and neuromodulation technologies. For its Cornerstone Robotics partnership around Sentire, along with expansion of its own Hugo system, the company will be up against Intuitive Surgical which is a well-established leader in the market. See how Medtronic is adding new catalysts to its already strong core business.
Medtronic Lags the Market Despite Solid Fundamentals
The medical device giant stands with almost $109.3 billion market capitalization, despite a rough stretch during 2026. The stock is down 9% on year-to-date basis and has lagged the broader market. However, the business fundamentals remain respectable, if not spectacular. The company has delivered $37.54 billion revenue over the prior twelve months, along with solid profitability. Operating margin stood at 19.33%, while the net margin was 13.93%.
Valuation makes the investment case more interesting. The stock trades at a trailing price-to-earnings multiple of 22x. However, there is encouragement from its forward P/E ratio which sits at 14.93x. The lower forward multiple reflects expectations for stronger earnings, although the trailing and forward ratios are not directly comparable because they may use different earnings measures. Investors would find the stock valued cheaply at present if such projections are realized. That’s why MDT ranked #8 on our list of the 10 Most Undervalued NYSE Stocks To Buy.
Institutional Sentiment
Data tracked across 1,000+ hedge funds by Insider Monkey reveals an increasing number of smart money managers invested in the company. As per 13F filing data for Q2 2026, a total of 67 hedge funds held positions in the stock compared to 60 by the end of the first quarter.
As per Yahoo Finance database, BlackRock is the largest institutional investor with 114.02 million shares, representing 8.91% of outstanding shares. Other notable institutional names include Vanguard Capital Management and State Street Corporation that hold 6.55% and 4.96% of outstanding shares, respectively.
Way Forward
The company’s newest growth engines include robotic surgery, pelvic health and cardiac ablation. Moreover, they are able to offset the weakness seen in some other segments like structural heart and neuromodulation. The broader investor sentiment now hinges on advanced surgical solutions, accretive deals and AI-enabled advancements across its product lineup.
While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Industrial Stocks With More Than 50% Upside and 10 Best Stocks Under $10 That Could Triple.
Hedge Fund Resource Center